Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections.
作者信息
White D J, Habib A R, Vanthuyne A, Langford S, Symonds M
机构信息
Department of Sexual Medicine, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK.
出版信息
Sex Transm Infect. 2001 Jun;77(3):212-3. doi: 10.1136/sti.77.3.212.
Abstract
Patients with vaginitis due to highly azole resistant Candida glabrata can be particularly difficult to treat. We describe three cases of longstanding vaginal candidiasis due to C glabrata. These had failed to respond to local and systemic antifungals. Flucytosine (1 g) and amphotericin B (100 mg) formulated in lubricating jelly base in a total 8 g delivered dose, was used per vagina once daily for 14 days with significant improvement, both clinically and microbiologically.
摘要
相似文献
1
Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections.
Sex Transm Infect. 2001 Jun;77(3):212-3. doi: 10.1136/sti.77.3.212.
2
Treatment of Candida glabrata using topical amphotericin B and flucytosine.
Sex Transm Infect. 2003 Jun;79(3):265-6. doi: 10.1136/sti.79.3.265-a.
3
A case series of the management of symptomatic azole-resistant candida.
Int J STD AIDS. 2012 May;23(5):375-6. doi: 10.1258/ijsa.2009.009441.
4
Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine.
Am J Obstet Gynecol. 2003 Nov;189(5):1297-300. doi: 10.1067/s0002-9378(03)00726-9.
5
Prevalence and management of non-albicans vaginal candidiasis.
Sex Transm Infect. 2010 Apr;86(2):99-100. doi: 10.1136/sti.2009.040386.
6
Refractory urinary tract and vulvovaginal infection caused by Candida krusei.
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Nov;20(11):1379-81. doi: 10.1007/s00192-009-0869-y. Epub 2009 Apr 1.
7
Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
Mycoses. 2015 Mar;58 Suppl 1:1-15. doi: 10.1111/myc.12292.
8
Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories.
Am J Obstet Gynecol. 2005 Jun;192(6):2009-12; discussion 2012-3. doi: 10.1016/j.ajog.2005.03.034.
9
Treatment of refractory Candida krusei vaginitis with topical amphotericin B.
Med Clin (Barc). 2016 Dec 16;147(12):565-566. doi: 10.1016/j.medcli.2016.06.029. Epub 2016 Aug 24.
10
[INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Akush Ginekol (Sofiia). 2016;55(4):20-29.
引用本文的文献
1
Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment.
Clin Microbiol Rev. 2025 Jun 12;38(2):e0028424. doi: 10.1128/cmr.00284-24. Epub 2025 Apr 22.
2
Flucytosine and its clinical usage.
Ther Adv Infect Dis. 2023 Apr 5;10:20499361231161387. doi: 10.1177/20499361231161387. eCollection 2023 Jan-Dec.
3
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Mycopathologia. 2023 Apr;188(1-2):99-109. doi: 10.1007/s11046-022-00687-w. Epub 2022 Nov 15.
4
Review on Plant-Based Management in Combating Antimicrobial Resistance - Mechanistic Perspective.
Front Pharmacol. 2022 Sep 29;13:879495. doi: 10.3389/fphar.2022.879495. eCollection 2022.
5
Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.
J Fungi (Basel). 2022 Feb 21;8(2):212. doi: 10.3390/jof8020212.
6
Combination of Miconazole and Domiphen Bromide Is Fungicidal against Biofilms of Resistant spp.
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.01296-20.
7
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16.
8
Effects of antifungal agents alone and in combination against Candida glabrata strains susceptible or resistant to fluconazole.
Mycopathologia. 2012 Sep;174(3):215-21. doi: 10.1007/s11046-012-9538-7. Epub 2012 Apr 22.
9
Local treatment of vulvovaginal candidosis : general and practical considerations.
Drugs. 2008;68(13):1787-802. doi: 10.2165/00003495-200868130-00002.
本文引用的文献
1
What to do with the patient with recurrent vulvovaginal candidiasis.
Sex Transm Infect. 1999 Aug;75(4):225-7. doi: 10.1136/sti.75.4.225.
2
Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid.
Eur J Clin Microbiol Infect Dis. 1999 Jan;18(1):59-61. doi: 10.1007/s100960050227.
3
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.
Clin Microbiol Rev. 1999 Jan;12(1):80-96. doi: 10.1128/CMR.12.1.80.
4
Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata.
Genitourin Med. 1993 Apr;69(2):112-4. doi: 10.1136/sti.69.2.112.
5
Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.
J Med Vet Mycol. 1994;32(4):267-74.
6
Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida.
Genitourin Med. 1995 Oct;71(5):304-7. doi: 10.1136/sti.71.5.304.
7
Topical flucytosine therapy for chronic recurrent Candida tropicalis infections.
J Reprod Med. 1986 Sep;31(9):821-4.
8
Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata.
J Antimicrob Chemother. 1986 Oct;18 Suppl B:39-49. doi: 10.1093/jac/18.supplement_b.39.
9
Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents.
Obstet Gynecol. 1990 Oct;76(4):651-5.
Zotero 插件